Impact of nucleotide metabolism on bacterial clearance
核苷酸代谢对细菌清除的影响
基本信息
- 批准号:10681286
- 负责人:
- 金额:$ 41.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AnimalsAnti-Inflammatory AgentsAutoimmune DiseasesCell RespirationCellsCommunicable DiseasesDihydroorotate dehydrogenaseDiseaseESKAPE pathogensFamilyFrightGoalsGrowthHumanImmunityImpairmentInfectionInfection ControlInfection preventionInflammationInflammatoryKnowledgeLaboratoriesLeukocytesLungLung infectionsMalignant NeoplasmsMeasuresMetabolicMetabolismMicrobial BiofilmsMucous MembraneMulti-Drug ResistanceNucleic AcidsNucleotidesOrganismOutcomeOxidative RegulationPathogenesisPathologyPathway interactionsPhysiological ProcessesPneumoniaPropertyProtein DephosphorylationPseudomonas aeruginosaPseudomonas aeruginosa pneumoniaPulmonary InflammationPurinesPyrimidinePyrimidinesReactionReactive Oxygen SpeciesResearchRespiratory MucosaRoleRouteSignal TransductionSignaling MoleculeStaphylococcus aureusTissuesToxinVirulencecancer celldesignecto-nucleotidaselung healthlung injurylung pathogenmetabolomicsnovel therapeuticsnucleotide metabolismoxidationpathogenpreventresponsetranscriptomicstumor
项目摘要
Project Summary
In my laboratory, we study how host metabolism determines the outcome of infectious diseases, such as during
pneumonia. Pneumonia is a brisk inflammatory reaction to airway pathogens that, if not adequately regulated,
can predispose to infection by opportunists that exploit airway oxidation to persist, such as Pseudomonas
aeruginosa and Staphylococcus aureus, which belong to the feared family of multidrug-resistant ESKAPE
pathogens. In response to the oxidative metabolism of airway cells, these organisms activate many mechanisms
of virulence that favor their survival in the human lung, such as toxins and biofilms, which exacerbate the damage
of the respiratory mucosa. Although it is known how these opportunists exploit airway damage to persist, it
remains poorly understood how the host eradicates infections by controlling these pro-oxidant pathways. In the
5 years contemplated for this project, we will address how regulation of oxidative metabolism in airway cells
limits bacterial persistence, and how we can use this knowledge to design new therapies to eradicate pulmonary
infections by ESKAPE pathogens. Nucleotides, like purines and pyrimidines, are not only used by cells to
generate nucleic acids to grow, but also to supervise many physiological processes, such as inflammation.
Indeed, in many autoimmune diseases, anti-inflammatory nucleotide signaling is severely impaired, causing
tissue oxidation and mucosal damage. These strong anti-inflammatory properties of certain nucleotidic routes
are also exploited by tumors to evade host immunity. In order to suppress the activation of anti-tumor leukocytes,
malignant cells co-opt both dihydroorotate dehydrogenase (DHODH) and the ecto-nucleotidase CD73, which
are two major components of the de novo pathway of pyrimidine synthesis and the purine dephosphorylation
route, respectively. While the regulatory roles of DHODH and CD73 are well appreciated in cancer and
autoimmune diseases, their activities in other major inflammatory pathologies, like pneumonia, remains unclear.
Here, we will progress in the research line of my laboratory by establishing that nucleotide metabolism through
both DHODH and CD73 is critical in the protection of the host lung against pneumonia by P. aeruginosa and S.
aureus. We will demonstrate that both DHODH and CD73 limit the detrimental oxidative metabolism of airway
cells, thus preventing from activation of mechanisms of pathogenesis by ESKAPE opportunists that feed off lung
damage to cause disease, like toxin synthesis and biofilms. We will accomplish these goals by performing
transcriptomic and metabolomics analyses in the airway of infected both controls and DHODH/CD73-deficient
animals, in which we will measure the host and bacterial networks related with oxidative metabolism, host
immunity, and pathogen virulence. Thus, in this project, we will establish the impact of nucleotide metabolism in
lung health against pulmonary pathogens, which will provide us both a metabolic framework to better understand
the pathology of pneumonia and new targets to clear infection produced by these opportunists.
项目总结
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sebastian Alejandro Riquelme Colet其他文献
Sebastian Alejandro Riquelme Colet的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 41.13万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 41.13万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 41.13万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 41.13万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 41.13万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 41.13万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 41.13万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 41.13万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 41.13万 - 项目类别: